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ABSTRACT
Objectives To investigate psychotropic prescribing in 
the intellectual disabilities population over 10 years, and 
associated mental ill health diagnoses.
Design Comparison of cross- sectional data in 2002–2004 
(T1) and 2014 (T2). Longitudinal cohort study with detailed 
health assessments at T1 and record linkage to T2 
prescribing data.
Setting General community.
Participants 1190 adults with intellectual disabilities in 
T1 compared with 3906 adults with intellectual disabilities 
in T2. 545/1190 adults with intellectual disabilities in T1 
were alive and their records linked to T2 prescribing data.
Main outcome measures Encashed regular and as- 
required psychotropic prescriptions.
Results 50.7% (603/1190) of adults in T1 and 48.2% 
(1881/3906) in T2 were prescribed at least one 
psychotropic; antipsychotics: 24.5% (292/1190) in T1 
and 16.7% (653/3906) in T2; antidepressants: 11.2% 
(133/1190) in T1 and 19.1% (746/3906) in T2. 21.2% 
(62/292) prescribed antipsychotics in T1 had psychosis 
or bipolar disorder, 33.2% (97/292) had no mental ill 
health or problem behaviours, 20.6% (60/292) had 
problem behaviours but no psychosis or bipolar disorder. 
Psychotropics increased from 47.0% (256/545) in T1 to 
57.8% (315/545) in T2 (p<0.001): antipsychotics did not 
change (OR 1.18; 95% CI 0.87 to 1.60; p=0.280), there 
was an increase for antidepressants (OR 2.80; 95% CI 
1.96 to 4.00; p<0.001), hypnotics/anxiolytics (OR 2.19; 
95% CI 1.34 to 3.61; p=0.002), and antiepileptics (OR 
1.40; 95% CI 1.06 to 1.84; p=0.017). Antipsychotic 
prescribing increased for people with problem behaviours 
in T1 (OR 6.45; 95% CI 4.41 to 9.45; p<0.001), more so 
than for people with other mental ill health in T1 (OR 4.11; 
95% CI 2.76 to 6.11; p<0.001).
Conclusions Despite concerns about antipsychotic 
prescribing and guidelines recommending their 
withdrawal, it appears that while fewer antipsychotic 
prescriptions were initiated by T2 than in T1, people were 
not withdrawn from them once commenced. People with 
problem behaviours had increased prescribing. There was 
also a striking increase in antidepressant prescriptions. 
Adults with intellectual disabilities need frequent and 
careful medication reviews.
INTRODUCTION
Mental ill health is common in people with 
intellectual disabilities.1 The prevalence of 
psychosis in this population is reported to 
be around 4% based on cross- sectional data, 
and the rate of people with a first psychotic 
episode is about 10 times that of the general 
population.2 While the rates of psychosis 
are relatively high, antipsychotics are often 
prescribed for adults with intellectual disabili-
ties who do not have a record of severe mental 
ill health,3 4 often for problem behaviours,5–9 
and despite limited evidence to support their 
use beyond short- term sedation.7 Indeed, 
71% of people with intellectual disabilities 
who are prescribed antipsychotics have been 
reported to have no record of serious mental 
ill health.10 This is important because antipsy-
chotics have numerous disabling, painful and 
disfiguring side effects, some of which are life 
Strengths and limitations of this study
 ► The large cohort size, longitudinal design, detailed 
ascertainment of the population with intellectual 
disabilities, and the in- depth health assessments at 
T1.
 ► The cross- sectional cohorts were population based 
at T1 and T2, and representative of the population 
with intellectual disabilities; the linked cohort had 
similar characteristics to the cross- sectional cohort 
at T1, suggesting this cohort is also representative 
and therefore that the results are generalisable.
 ► Only 73% of general practices agreed to data ex-
traction, and this combined with deaths are likely 
to be the main reasons for 545/1190 of the partici-
pants being linked in the T2 data 10 years later.
 ► The different methods of data collection, with spe-
cialist individual assessments at T1 and electronic 
data extraction at T2; in particular, a large proportion 
of information is missing and inaccuracies might 
exist relating to recorded level of intellectual disabil-
ities in the general practitioner data at T2, limiting 
comparability of this variable between the T1 and 
T2 cohorts.
 ► The study did not investigate changes in dosages, 
polypharmacy or duration of use, and mental ill 
health data at T2 are lacking.
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threatening, such as tardive dyskinesia, cardiac arrhyth-
mias and sudden cardiac death.11–13 Antipsychotics are 
also frequently prescribed for children and young people 
with a range of developmental disabilities and problem 
behaviours,14 15 and in the young general population, 
rates increase during adolescence.16
Concerns have repeatedly been raised about the 
overuse of antipsychotics, and the need for more propor-
tionate prescribing for people with intellectual disabili-
ties.7 17–19 In 2016 a national campaign was launched by 
NHS England in partnership with the Royal Colleges of 
General Practitioners, Psychiatrists, and Nursing, the 
Royal Pharmaceutical Society, and the British Psycholog-
ical Society to address these concerns in England: ‘Stop-
ping over medication of people with a learning disability, 
autism or both (STOMP)’. Guidelines from STOMP, 
the National Institute for Health and Care Excellence, 
and the Royal College of Psychiatrists highlight that 
prescribers, where appropriate, should reduce or with-
draw antipsychotics for people with intellectual disabili-
ties who do not have psychosis.7 20 21 However, there is very 
little empirical evidence from the UK on any changes in 
antipsychotic prescribing patterns over time. An excep-
tion is a study by Sheehan and colleagues that extracted 
data from general practice records on 33 016 adults with a 
record of intellectual disabilities, with a median follow- up 
of 5.5 years.10 These authors reported the incidence of 
new psychotropic prescription to be 518/10 000 person 
years. Prescriptions of antipsychotics fell by 4% per year 
over the study period, as did mood stabilisers, while there 
was no consistent trend for antidepressants or anxio-
lytics/hypnotics. Sheehan and colleagues reported that 
47% of those with ‘challenging behaviour’ had received 
antipsychotic drugs, but only 12% had a record of severe 
mental ill health, and that 26% of those prescribed anti-
psychotics did not have a record of severe mental ill health 
or ‘challenging behaviour’. A limitation of this study is 
in the identification of ‘challenging behaviour’ through 
a heterogeneous list of 45 Read codes (the system used 
in general practices in the UK to code diagnoses). Read 
codes do not provide a robust method for ascertaining 
problem behaviours. Additionally, incomplete and vari-
able recording practices do not always accurately reflect a 
person’s health.10
Another study from Australia investigated psychotropic 
medication use between 1999 and 2015 in a cohort of 138 
participants22 and also found a strong association between 
problem behaviours and psychotropic medication. In this 
cohort the study reported that once psychotropic medica-
tions were prescribed they were unlikely to be removed, 
and little change was observed in prescribing of antipsy-
chotics between 1999 and 2015 (24/138 (24%) to 23/92 
(23%)). A sharp increase in the prescribing of antide-
pressants from 16.7% to 36.1% across the same period 
was also observed. However, while this was a longitudinal 
cohort, not all participants took part in all waves of data 
collection, therefore it is not possible to ascertain within 
group changes in prescribing.
Aim
The aim of this study was to investigate changes over a 
decade in psychotropic prescribing for adults with intel-
lectual disabilities, and the diagnoses associated with anti-
psychotics by using detailed psychiatric assessments.
METHODS
Ethical approval
Between 2002 and 2004 (T1), individual consent to 
participate was taken in line with Scottish law. In 2014 
(T2), 191/263 (73%) general practices in NHS Greater 
Glasgow and Clyde area participated, and the NHS 
Greater Glasgow and Clyde Local Privacy Advisory 
Committee approved electronic extraction and linkage 
of primary care records.
Participants
In 2000–2001, a primary care intellectual disabilities 
register was established of adults with intellectual disabil-
ities, aged 16 years and older, living in the NHS Greater 
Glasgow area. This initiative was delivered through part-
nership between the intellectual disabilities clinical 
service and all general practitioners in the area. People 
with intellectual disabilities were identified through social 
work services for people with intellectual disabilities; local 
authority funding arrangements for people receiving 
paid support of any kind, including day opportunities; 
local specialist health services for people with intellectual 
disabilities; the Health Board; and general practices who 
were financially incentivised to identify their registered 
patients with intellectual disabilities (100% of general 
practices participated). Intellectual disabilities nurses 
reviewed all cases on the register to determine if intel-
lectual disabilities were present; those that did not have 
intellectual disabilities were removed from the register. 
The register was then updated annually by the general 
practices and the intellectual disabilities clinical service.
Between 2002 and 2004, the register was used to invite 
people living in a representative part of the Health 
Board area to participate in the study; 67% agreed to 
take part. These participants were recruited to a longi-
tudinal cohort between 2002 and 2004 (T1), and had 
detailed health assessments at that time; 1190 were aged 
18 years and older and comprise the study population 
reported here. In 2014 (T2), for people on the register 
and living in the Health Board area, data were extracted 
from primary care records; 73% of general practices in 
the Health Board area agreed to the data extraction. Data 
were extracted on 3906 patients with intellectual disabil-
ities aged 18 years and older, who comprise the study 
population reported here.
Process and measures
Semi- structured individual health assessments, including 
medication review, assessment of level of intellectual 
disabilities (via structured questions on abilities, and the 
Vineland Scale23), mental ill health symptoms including 
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problem behaviours and autism, were conducted at T1 
by one of six intellectual disabilities nurses and one of 
three general practitioners with a special interest in intel-
lectual disabilities. These assessments were preceded by 
data collection from the person’s general practitioner 
medical records, and then a review conducted with the 
person with intellectual disabilities and their carer(s). 
This included a review of drug charts for participants in 
supported care. The 54% of individuals identified with 
possible, probable or definite mental ill health (including 
problem behaviours and autism) were then assessed by 
the study psychiatrists who were specialists in intellectual 
disabilities psychiatry. Information from each person’s 
psychiatric assessment was reviewed by two psychiatrists 
who had a case conference and agreed the classifica-
tion of the mental ill health using ICD-10- DCR,24 DSM- 
IV- TR,25 DC- LD26 and clinical criteria. Details have been 
previously reported.1 Given that ICD-10 and DSM criteria 
function poorly for adults with moderate to severe intel-
lectual disabilities (particularly with regards to problem 
behaviours), in this study we report the clinical diagnoses 
agreed by the study psychiatrists. Data collection was over 
a 2- year period. Drugs were coded using British National 
Formulary (BNF) codes.
At T2, the 3906 adults with intellectual disabilities 
identified from primary care records were record linked 
to Prescribing Information System (PIS) data by using 
the Community Health Index (CHI), which is the NHS 
patient identification number, unique to each person. PIS 
is Scotland’s electronic record of all encashed prescrip-
tions (ie, not prescriptions issued, or drugs adminis-
tered, but those that the carers/person with intellectual 
disabilities actually took to a pharmacist and exchanged 
for the drugs), and includes a record of the BNF code 
of each prescribed drug.27 Prescribing information was 
then extracted using BNF codes for the 3906 adults with 
intellectual disabilities to identify all prescriptions of anti-
psychotics, antidepressants, antiepileptics, lithium, and 
hypnotics/anxiolytics across a specific 12- week prescribing 
window in 2014, including both regular prescriptions and 
as- required medication. To establish the longitudinal 
cohort the CHI number was used to identify T1 partici-
pants in the T2 dataset, enabling comparison of encashed 
medications across the decade. Only participants with 
complete data who were aged 18 years and older were 
included in the analyses (figure 1).
Statistical analysis
Subject characteristics and prescribing information were 
summarised descriptively with mean and SD for contin-
uous outcomes and number and percentage for categor-
ical outcomes at each time point (T1 and T2). Prescribing 
information at each time point was summarised using 
binary variables for each class of medications of interest 
(yes/no), allowing prescribing patterns to be inves-
tigated between the two time points in the study using 
McNemar’s tests on the subset of the linked cohort, for 
whom there were prescribing records at both T1 and 
Figure 1 Participant flow diagram. GG&C, Greater Glasgow and Clyde.
 o
n
 Septem
ber 22, 2020 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2020-036862 on 10 September 2020. Downloaded from 
4 Henderson A, et al. BMJ Open 2020;10:e036862. doi:10.1136/bmjopen-2020-036862
Open access 
T2. This analysis was extended to explore whether there 
were associations between time or the subject character-
istics at T1, with each prescription category using binary 
logistic regression models. Each model included multiple 
explanatory variables; specifically, time as a binary vari-
able to indicate each time point T1 and T2; sex; age as 
a continuous measure; level of intellectual disabilities 
as four- level categorical variable; presence of mental ill 
health (yes/no, excluding problem behaviours); having 
problem behaviours (yes/no); and a binary dependant 
variable for each class of medication (yes/no). Logistic 
regression models were also fitted with the above T1 
subject characteristics to explore their association with 
each prescribing category specifically at T2. Odds ratios 
are reported for all logistic regression models with corre-
sponding 95% confidence intervals (CIs) and p values. A 
p value less than 0.05 is considered statistically significant. 
Statistical analyses were conducted using SAS version 9.3.
Patient and public involvement
The Scottish Learning Disabilities Observatory has a 
steering committee which meets twice a year and provides 
strategic direction and oversight of all of the Observatory’s 
research, including this project. The steering committee 
includes people with intellectual disabilities from ‘People 
First’, a national group of self- advocates with intellectual 
disabilities.
RESULTS
Participant characteristics of the cross-sectional cohorts
Data for those who had incomplete data at T1 and for 
those who were aged under 18 years at either time point 
were excluded from further analyses. Table 1 shows 
participant characteristics: age, sex, level of intellectual 
disabilities at T1 (n=1190) and T2 (n=3906), and mental 
ill health and epilepsy diagnoses at T1. No mental health 
or epilepsy data were available at T2.
Prescribing for the cross-sectional cohorts
At least one psychotropic was prescribed at T1 for 50.7% 
(603/1190) and at T2 for 48.2% (1881/3906) (table 2) 
of participants. Antipsychotics were prescribed to 24.5% 
(292/1190) of participants at T1 and 16.7% (653/3906) 
at T2. At T1, antidepressants were prescribed for 11.2% 
(133/1190) and at T2 for 19.1% (746/3906) of partic-
ipants. Hypnotic/anxiolytic, lithium and anti- epileptic 
prescribing was similar at T1 and T2.
The types of mental ill health experienced by the 292 
participants at T1 who were taking antipsychotics are 
shown in table 3. The most common diagnosis within this 
group was problem behaviours at 40.8% (119/292). Of 
note, 33.2% (97/292) of the people taking antipsychotics 
did not have any identified mental ill health or problem 
behaviours. Figure 2 demonstrates the overlap between 
groups of the people who were taking antipsychotics at 
T1 and selected diagnoses.
Table 3 also shows the types of mental ill health expe-
rienced by the 230 participants at T1 who were taking 
antipsychotics, after excluding people with psychosis (or 
psychosis in remission) or bipolar disorder (given that 
they would be expected to be prescribed antipsychotics, 
and given the considerable overlap between disorders 
shown in figure 2). Most strikingly, 97/230 (42.2%) of 
those prescribed antipsychotics had no mental ill health 
or problem behaviours. The proportion of people in 
each diagnostic category, without co- occurring psychosis 
or bipolar disorder who were taking antipsychotics was 
considerable for all types of mental ill health: 11.7% 
(27/230) for autism, 7.0% (16/230) for unipolar depres-
sion, 2.6% (6/230) for anxiety disorders and 2.2% 
(5/230) or less for all other diagnoses.
Table 1 Participant characteristics for the cross- sectional 
cohorts at T1 and T2
Characteristic
T1 aged
≥18 years
T2 aged
≥18 years
(n=1190) (n=3906)
Age, mean (SD) 44.6 (14.3) 45.4 (15.5)
Sex, No (%)
  Male 671 (56.4) 2260 (57.9)
  Female 519 (43.6) 1646 (42.1)
Level of intellectual disabilities, No (%)
  Mild 451 (37.9) 1047 (26.8)
  Moderate 319 (26.8) 859 (22.0)
  Severe 233 (19.6) 595 (15.2)
  Profound 187 (15.7) 197 (5.0)
  Unknown 0 1208 (30.9)
Epilepsy, No (%) 419 (35.2%) Not collected
Type of mental ill health, No (%)
  Psychosis, including 
psychosis in remission
52 (4.4) Not collected
  Problem behaviours 244 (20.5)   
  Autism 80 (6.7)
  Attention deficit 
hyperactivity disorder
15 (1.3)
  Unipolar depression 51 (4.3)
  Bipolar disorder 21 (1.8)
  Anxiety disorders 32 (2.7)
  Organic disorder 20 (1.7)
  Personality disorder 9 (0.8)
  Obsessive compulsive 
disorder
7 (0.6)
  Psychosexual disorder <5
  Other 15 (1.3)
  Mental ill health (including 
problem behaviours)
438 (36.8)
  Mental ill health (excluding 
problem behaviours)
194 (16.3)
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Participant characteristics of the longitudinal, linked cohort
The longitudinal, linked cohort included the 545 adults 
who were in the T1 cohort and who were also identified 
within the GP records at T2. Table 4 shows their age, 
sex, level of intellectual disabilities, epilepsy diagnosis 
and mental ill health at T1. They appear to be broadly 
representative of the whole cohort at T1 based on these 
characteristics.
Prescribing for the longitudinal, linked cohort
At least one psychotropic medication was prescribed 
for 47.0% (256/545) at T1 and for 57.8% (315/545) at 
Table 4 Participant characteristics at T1 for people in the 
longitudinal cohort
Characteristic
T1 (aged ≥18 years)
n=545 (%)
Age, mean (SD) 41.8 (13.2)
Sex, No (%)
  Male 322 (59.1)
  Female 223 (40.9)
Level of intellectual disabilities, No (%)
  Mild 237 (43.5)
  Moderate 154 (28.3)
  Severe 89 (16.3)
  Profound 65 (11.9)
Epilepsy, No (%) 173 (31.7)
Type of mental ill health, No (%)
  Psychosis, including psychosis in 
remission
32 (5.9)
  Problem behaviours 109 (20.0)
  Autism 38 (7.0)
  Attention deficit hyperactivity disorder 8 (1.5)
  Unipolar depression 23 (4.2)
  Bipolar disorder 10 (1.8)
  Anxiety disorders 14 (2.6)
  Organic disorder <5
  Personality disorder 7 (1.3)
  Obsessive compulsive disorder <5
  Psychosexual disorder <5
  Other 6 (1.1)
  Mental ill health (including problem 
behaviours)
190 (34.9)
  Mental ill health (excluding problem 
behaviours)
81 (14.9)
Table 2 Psychotropics prescribed for the cross- sectional 
cohorts at T1 and T2
Prescriptions
T1 aged ≥18 
years
(n=1190)
T2 aged ≥18 
years
(n=3906)
Any psychotropic drug 603 (50.7) 1881 (48.2)
Antipsychotics 292 (24.5) 653 (16.7)
Antidepressants 133 (11.2) 746 (19.1)
Antiepileptics 333 (28.0) 1028 (26.3)
Lithium 14 (1.2) 31 (0.8)
Hypnotics/anxiolytics 81 (6.8) 305 (7.8)
Missing data 0 3 (0.1)
Table 3 Types of mental ill health at T1 experienced by 
people prescribed antipsychotics at T1, and after excluding 
people with psychosis and bipolar disorder
Mental ill health at T1
Adults (≥18 years) taking 
antipsychotics at T1
Diagnosis
All
(n=1190)
All
(n=292)
Excluding people 
with psychosis and 
bipolar disorder
(n=230)
Psychosis, including 
psychosis in remission
52 45 (15.4) –
Problem behaviours 244 119 (40.8) 100 (43.5)
Autism 80 30 (10.3) 27 (11.7)
Attention deficit 
hyperactivity disorder
15 12 (4.1) 11 (4.8)
Unipolar depression 51 20 (6.9) 16 (7.0)
Bipolar disorder 21 17 (5.8) –
Anxiety disorders 32 7 (2.4) 6 (2.6)
Organic disorder 20 5 (1.7) <5
Personality disorder 9 5 (1.7) <5
Obsessive compulsive 
disorder
7 3 (1.0) <5
Psychosexual disorder <5 <5 <5
Other 15 6 (2.1) 5 (2.2)
Mental ill health 
(including problem 
behaviours)
438 195 (66.8) 133 (57.8)
Mental ill health 
(excluding problem 
behaviours)
194 76 (26.3) 33 (14.4)
No mental ill health or 
problem behaviours
752 97 (33.2) 97 (42.2)
Figure 2 Types of mental ill health experienced by people 
prescribed antipsychotics at T1 (n=292)
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T2 (table 5), which is a significant increase over time 
(p<0.001). Antidepressants were prescribed for 9.9% 
(54/545) of participants at T1 and for 22.0% (120/545) 
at T2, showing a significant increase (p<0.001). At T1, 
hypnotics/anxiolytics were prescribed for 4.6% (25/545) 
of participants, and at T2 for 9.4% (51/545), a significant 
increase (p<0.001). At T1, antiepileptics were prescribed 
for 24.8% (135/545) of participants, and at T2 for 31.0% 
(169/545), a significant increase (p<0.001). Prescribing 
patterns at T1 and T2 were similar for both antipsychotics 
and lithium. Of the 128 people prescribed antipsychotics 
at T1, 77.3% (99/128) were prescribed antipsychotics at 
T2; only 29 (22.7%) had been withdrawn, and 43/545 
(7.9%) had started on an antipsychotic between the two 
timepoints.
The logistic regression analyses, taking account of 
sex, age, level of intellectual disabilities, having mental 
ill health (excluding problem behaviours) and having 
problem behaviours at T1 (table 6) show no significant 
difference in antipsychotic prescribing rate in the linked 
cohort over the decade (OR=1.18; 95% CI 0.87 to 1.60; 
p=0.280), an increase in antidepressants (OR 2.80; 95% 
CI 1.96 to 4.00; p<0.001), hypnotics/anxiolytics (OR 
2.19; 95% CI 1.34 to 3.6; p=0.002), and antiepileptic 
prescribing (OR 1.40; 95% CI 1.06 to 1.84; p=0.017). Sex 
was not independently associated with prescribing, except 
that women were more likely to have an increase in anti-
depressants than men after adjusting for time (OR 0.53; 
95% CI 0.37 to 0.78; p<0.001). Older age had a small effect 
on prescribing for antipsychotics and antidepressants.
Effects are also observed for level of intellectual disabil-
ities. There was a gradient for antiepileptics (increased 
prescribing with increasing severity of intellectual 
disabilities) and a gradient for antidepressants (reduced 
prescribing with increasing severity of intellectual disabil-
ities). However, there was no gradient across different 
ability levels for antipsychotic prescribing. As expected, 
participants with a diagnosed mental health problem 
(excluding problem behaviours) at T1 were more likely 
to be prescribed antipsychotics (OR 4.11; 95% CI 2.76 to 
6.11; p<0.001), antidepressants (OR 3.90; 95% CI 2.53 
to 6.02; p<0.001), and hypnotics/anxiolytics (OR 3.25; 
95% CI 1.78 to 5.94; p<0.001). Strikingly though, people 
with problem behaviours identified at T1 were over six 
Table 5 Psychotropic medications prescribed for the 
longitudinal, linked cohort at T1 and T2
Medication group
T1
(n=545)
T2
(n=545) p- value
Any psychotropic 
medication
256 (47.0%) 315 (57.8%) p<0.001
Antipsychotics 128 (23.5%) 142 (26.1%) p=0.099
Antidepressants 54 (9.9%) 120 (22.0%) p<0.001
Hypnotics/anxiolytics 25 (4.6%) 51 (9.4%) p<0.001
Antiepileptics 135 (24.8%) 169 (31.0%) p<0.001
Lithium 7 (1.3%) 10 (1.8%) p=0.180
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times more likely to have increased prescribing of an 
antipsychotic (OR 6.45; 95% CI 4.41 to 9.45; p<0.001), 
over three times more likely for antidepressants (OR 3.44; 
95% CI 2.22 to 5.35; p<0.001) and three times more likely 
for hypnotics/anxiolytics (OR 3.06; 95% CI 1.72 to 5.44; 
p<0.001).
The further regression (online supplementary table 
1) investigating factors at T1 which are associated with 
prescribing at T2 (as opposed to change in prescribing 
reported in the paragraph above) shows that women 
were more likely to be prescribed antidepressants at T2, 
that older age had a small effect for antipsychotics and 
antidepressants at T2, a gradient across ability level for 
antiepileptics, a relationship with moderate and severe 
(but not profound) intellectual disabilities for antipsy-
chotics at T2, and fewer antidepressants for people with 
profound intellectual disabilities. Mental ill health and 
problem behaviours at T1 predicted prescribing of all 
classes.
DISCUSSION
Principal findings
Despite numerous calls and guidelines in the UK for the 
withdrawal of antipsychotic drugs from people with intel-
lectual disabilities who do not have psychosis/bipolar 
disorders,7 20 21 our longitudinal, linked cohort analysis 
shows no progress over a decade. The comparison of the 
two cross- sectional cohorts does show a lower rate of anti-
psychotic prescribing in T2 than was observed in T1, but 
the rate is still high in T2 at 16.7% of the population. It 
appears that while few people are being withdrawn from 
antipsychotics once they start them, new antipsychotic 
prescriptions are less commonly initiated than in the past. 
Over the decade, comparison of both the cross- sectional 
cohorts, and of the longitudinal, linked cohort, reveal a 
striking increase in the prescription of antidepressants 
(11.2% to 19.1%, and 9.9% to 22.0%). This was particu-
larly so for women and for people with mild intellectual 
disabilities. To a lesser extent, there were also increases in 
prescribing of hypnotics/anxiolytics and antiepileptics in 
the linked cohort, but not in the comparison of the cross- 
sectional cohorts. This difference may be accounted for 
by the known increase in these prescriptions with age,5 as 
the linked cohort is of course 10 years older in T2, whereas 
age and sex are similar in the whole cohorts in T2 and in 
T1. The age- related change in antiepileptic prescribing 
in the longitudinal linked cohort, but not in the compar-
ison of the similarly aged cross- sectional cohorts, contex-
tualises the antipsychotic and antidepressant findings 
(prescribing trends in general) because antiepileptics 
were almost all prescribed for the highly prevalent condi-
tion of epilepsy in this population. While previous studies 
have reported high rates of antipsychotic prescribing, we 
are not aware of any that have investigated prescribing 
over this length of time along with related fluctuations in 
assessed mental ill health.
Comparison with previous literature
To our knowledge only two studies have investigated longi-
tudinal psychotropic prescribing patterns in community- 
based samples of people with intellectual disabilities in the 
UK. Both studies were large and relied on data extracted 
from primary care records. One reported antipsychotic 
prescribing for 17.1%, and antidepressants for 16.9% of 
adults with intellectual disabilities, with age being associ-
ated with both, and sex with antidepressants, similar to 
our T2 results.5 The results of the other study differed, 
reporting antipsychotic prescribing in 27.7% of partici-
pants at the end of their study period, but also reporting 
a decrease of 4% per year over the whole study period, 
and no consistent trend in antidepressant prescriptions 
was reported.5 Neither study conducted psychiatric 
assessments on the population, limiting the precision of 
findings related to clinical diagnosis and GP- recorded 
symptoms.
This study reaffirms the strong association between anti-
psychotic prescribing and problem behaviours reported 
in a number of other studies.28–31 However, few studies 
have separately reported associations between problem 
behaviours and antidepressants or hynotics/anxiolytics. 
An Irish study which investigated rates of prescribing of 
psychotropics in older adults with intellectual disabilities 
reported no increased risk of antidepressant prescribing 
or any association with problem behaviours.32
Several studies have reported the increase in rates of 
antidepressant prescribing in the general population 
across the UK, which our findings mirror.33–35 In Scotland 
the number of antidepressant prescriptions rose from 
1.16 to 3.53 million per year between 1992 and 2006,36 and 
women were prescribed antidepressants more frequently 
than men.33 The reasons for the increase are unclear and 
have been attributed to multiple factors such as the avail-
ability of newer classes of drugs with fewer side effects, 
improved management of depression, lack of availability 
of alternative interventions,36 a widening of clinical 
uses33 and patient expectations. Earlier studies have cited 
concerns that depression may have been underdiagnosed 
in the population with intellectual disabilities.37 One 
American study which retrospectively analysed outpa-
tient psychiatric charts reported a higher than expected 
rate of antidepressant prescribing for the subgroup with 
intellectual disabilities and suggested this was indicative 
of increasing diagnosis of depressive disorders in adults 
with intellectual disabilities.38 Another US study analysed 
data from adults with intellectual disabilities living in 
community settings in New York State between 2006 and 
2007 and also reported a higher than expected rate of 
antidepressant prescribing in this group.39 The substan-
tial increase in antidepressant prescribing observed in the 
current study may indicate improved diagnosis in primary 
care for this population.24 This study has also observed 
that problem behaviours were independently associated 
with antidepressant prescribing in adults with intellectual 
disabilities. However a systematic review of antidepres-
sants and problem behaviour management in people 
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with intellectual disabilities concluded that evidence 
of their effectiveness in this context is lacking.40 Longi-
tudinal patterns of antidepressant prescribing require 
further investigation.
Strengths and limitations
Strengths of the study include its large size, the longitu-
dinal design, the detailed ascertainment of the popula-
tion with intellectual disabilities, and the detailed health 
assessments at T1. The cross- sectional cohorts were popu-
lation based at T1 and T2, and so were more widely repre-
sentative of the population with intellectual disabilities. 
Additionally, the linked cohort was similar in character-
istics to the whole cohort at T1, suggesting it is represen-
tative and hence that the results are generalisable. The 
12- week extraction period of PIS data was selected to 
account for the frequency of prescriptions being issued; 
it included both regular and as- required drugs. Given the 
12- week prescribing period it is likely that the as- required 
drugs were being actively used (as a fresh prescription had 
been issued and was encashed by the person with intel-
lectual disabilities/their carer during this period). The 
time period for encashment was identical at both time 
points for the longitudinal, linked cohort. As a matter of 
caution in interpreting the data, the case- conferenced 
clinical mental ill health diagnoses agreed by the study 
psychiatrists were used rather than ICD-10 or DSM- IV- TR 
diagnoses, in view of the under- recording of mental ill 
health that these two classification systems produce with 
this population; had we used either of these classifica-
tions, our results would have been even more striking in 
terms of the discrepancy between mental ill health and 
prescription of antipsychotics.
Only 73% of general practices agreed to data 
extraction, and this combined with deaths are likely to be 
the main reasons for 545/1190 of the participants being 
linked in the T2 data 10 years later. Limitations are the 
different methods of data collection, with specialist indi-
vidual assessments at T1 and electronic data extraction 
at T2. In particular,a large proportion of information is 
missing and there may be inaccuracies on the recorded 
level of intellectual disabilities in the general practi-
tioner data at T2, so comparison of this variable between 
the T1 and T2 cohorts is limited. Additionally, mental ill 
health data at T2 are lacking. The study did not investi-
gate changes in dosages, polypharmacy or duration of 
use. Some antipsychotic drugs are licenced for indica-
tions other than psychosis, and it is possible that other 
conditions accounted for their use, for example prom-
azine. Antidepressants and antiepileptics have also seen 
increased use in the general population over this time 
period for neuralgic pain. We do not know how relevant 
this is to people with intellectual disabilities who may 
have difficulties in communicating pain, and note that 
encashed antiepileptics did not increase between the 
two cohorts.
Implications for research and practice
This study has shown that fewer new antipsychotic 
prescriptions are being initiated, but patients prescribed 
antipsychotics in T1 were unlikely to have these drugs 
withdrawn over the next decade. This implies possible 
reluctance of carers, families and individuals to stop 
medications, combined with a lack of evidence available 
to prescribers about direct cessation interventions.22 41 
The issue therefore remains far from addressed, and the 
risks of long- term health problems, death and impact 
on quality of life associated with long- term antipsychotic 
prescriptions still need further highlighting.42 This study 
reinforces the need for frequent medication reviews for 
people with intellectual disabilities, alongside further 
research to investigate the long- term effects of antipsy-
chotic medications on this population.8 Further research 
to examine the barriers to antipsychotic drug reduction 
and to evaluate approaches to promoting reduction and 
withdrawal of antipsychotics for people with intellectual 
disabilities is needed. There is a dearth of evidence on 
antidepressant prescribing in the population with intel-
lectual disabilities. The sharp increase in antidepres-
sant prescribing observed in this study demands further 
research to understand the drivers for this practice. The 
association between increasing age and prescribing of 
antipsychotics and antidepressants also supports calls 
for research to investigate the implications of long- term 
psychotropic prescribing for older people with intellec-
tual disabilities.43
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